Neuwirt Hannes, Dr. Med. Univ.

University / Clinic: Innsbruck Medical University
Institute: Department of Urology
 
Research Area:

Email: hannes.neuwirt@uibk.ac.at
Web:  


Research Topic:
Thesis title: "SOCS and prostate cancer"

We are investigating a group of proteins called SOCS (Suppressor of Cytokine Signaling), which play a pivotal role as cytokine induced negative feedback regulators of e.g. interleukin 6. Primarily we want to elucidate the implication of SOCS-3 in the IL-6/JAK/STAT pathway and the influence of androgens on SOCS-3 expression in prostate cancer in vitro and in vivo.

Selected publications:
 
  Ofer P, Heidegger I, Eder I, Schöpf B, Neuwirt H, Geley S, Klocker H, Massoner P
Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo.
Mol Endocrinol. 2015 Dec;29(12):1694-707. doi: 10.1210/me.2015-1073. Epub 2015 Oct 9.

  Puhr M, Höfer J, Neuwirt H, Eder I, Kern J, Schäfer G, Geley S, Heidegger I, Klocker H, Culig Z
PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.
Oncotarget. 2014 Dec 15;5(23):12043-56.

  Puhr M, Höfer J, Schäfer G, Erb H, Oh S, Klocker H, Heidegger I, Neuwirt H, Culig Z
Epithelial to Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and is Mediated by Reduced Expression of miR-200c and miR-205.
Am J Pathol. 2012 Oct 3. pii: S0002-9440(12)00653-0. doi: 10.1016/j.ajpath.2012.08.011

  Puhr M, Santer F, Neuwirt H, Marcias G, Hobisch A, Culig Z
SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling.
Endocr Relat Cancer. 2010 May 18;17(2):525-38. Print 2010 Jun.

  Malinowska K, Neuwirt H, Cavarretta I, Bektic J, Steiner H, Dietrich H, Moser P, Fuchs D, Hobisch A, Culig Z
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor
Endocr Relat Cancer. 2009 Mar;16(1):155-69. Epub 2008 Nov 14.

  Neuwirt H, Puhr M, Cavarretta I, Mitterberger M, Hobisch A, Culig Z
[Androgens stimulate the expression of SOCS-3 and inhibits their effect on proliferation and secretion]
Aktuelle Urol. 2009 Aug;40(4):231-4. Epub 2009 Jul 24. German.

  Puhr M, Santer F, Neuwirt H, Susani M, Nemeth J, Hobisch A, Kenner L, Culig Z
Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.
Cancer Res. 2009 Sep 15;69(18):7375-84. Epub 2009 Sep 8.

  Neuwirt H, Puhr M, Santer F, Susani M, Doppler W, Marcias G, Rauch V, Brugger M, Hobisch A, Kenner L, Culig Z
Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.
Am J Pathol. 2009 May;174(5):1921-30. Epub 2009 Mar 26.

  Neuwirt H, Arias M, Puhr M, Hobisch A, Culig Z
Oligomeric proanthocyanidin complexes (OPC) exert anti-proliferative and pro-apoptotic effects on prostate cancer cells.
Prostate 2008 Nov 1;68(15):1647-54.

  Neuwirt H, Puhr M, Cavarretta I, Mitterberger M, Hobisch A, Culig Z
Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion.
Endocr Relat Cancer. 2007 Dec;14(4):1007-19

  Cavarretta I, Neuwirt H, Untergasser G, Moser P, Zaki M, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth J, Culig Z
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1
Oncogene 26:2822-2832. 2007.

  Bellezza I, Neuwirt H, Nemes C, Cavarretta I, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z
Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer.
Am J Pathol. 2006 Dec;169(6):2199-208.

  Bellezza I, Neuwirt H, Nemes C, Cavarretta I, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z
“Suppressor of cytokine signalling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer”
Am J Patho 2006 Dec;169(6):2199-208. *joint first authors

  Cavarretta I, Neuwirt H, Untergasser G, Moser P, Zaki M, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth J, Culig Z
“The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by mcl-1”
Oncogene. 2006 Oct 30; [Epub ahead of print]

  Neuwirt H, Müller H, Cavarretta I, Tiefenthaler M, Bartsch G, Konwalinka G, Culig Z
“Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway.“
Int J Onc. 2006 Aug;29(2):503-12.

  Müller H, Hofer S, Kaneider N, Neuwirt H, Mosheimer B, Mayer G, Konwalinka G, Heufler C, Tiefenthaler M
“The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells.“
Eur J Immunol. 2005 Feb; 35(2):533-45.